Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 605
- 试验地点
- 54
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
FIL_FOLL19 is an open-label, multicenter, randomized phase III trial. The sponsor of this clinical trial is Fondazione Italiana Linfomi (FIL).
The Primary Objective of the study is to demonstrate that, in patients with newly diagnosed, advanced stage Follicular Lymphoma (FL) with high tumor burden according to the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria, a treatment strategy that reduces the number of chemotherapy cycles in case of early response to immunochemotherapy is not inferior compared to standard therapy at full dose in terms of Progression-Free Survival (PFS).
详细描述
This is an open-label, multicenter, randomized phase III trial. The study plans to randomize patients with a 1:1 ratio to Arm A (Standard arm) or Arm B (Experimental arm).
Once randomized, each patient will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP) chosen by the physician on a patient basis before randomization.
Patients randomized to Arm A will receive an induction immunochemotherapy at full doses (standard schedule).
After cycle 4, patients will be assessed for response and will complete their planned therapy if at least a stable disease is confirmed.
Patients randomized to Arm B will start their induction treatment with 4 cycles of the immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be assessed for response and will proceed with subsequent treatment based on the quality of their response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically documented diagnosis of CD20+ Follicular lymphoma grade 1-2 or 3a, as defined in the 2017 edition of the World Health Organization (WHO) classification;
- •Age ≥ 18 years;
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Appendix B);
- •No previous immunochemotherapy for the lymphoma (localized radiotherapy or rituximab monotherapy with max of 4 doses are allowed);
- •Ann Arbor stage II-IV (Appendix A);
- •High tumor burden as per Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria defined as the presence of at least one of the following:
- •systemic symptoms;
- •Tumor bulk (any nodal or extranodal tumor mass with diameter > 7 cm);
- •involvement of ≥ 3 nodal sites, each with a diameter ≥ 3 cm;
- •splenomegaly;
- •compressive syndrome (organ compression);
- •serous effusion;
- •circulant malignant cells;
- •cytopenia;
- •Eastern Cooperative Oncology Group - Performance Status (ECOG-PS) > 1;
- •Lactate dehydrogenase (LDH) > upper limit of normality (ULN);
- •β2-microglobulin > 3 mg/L.
- •At least one site of measurable nodal disease at baseline ≥ 1.5 cm in the longest transverse diameter as determined by CT scan (MRI is allowed if CT scan cannot be performed); or evaluable disease at baseline FDG-PET (18F-fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)) scan (at least one metabolic active site of disease);
- •Adequate hematological counts (unless due to bone marrow involvement by lymphoma) defined as follows:
- •Absolute Neutrophil count (ANC) > 1.5 x 109/L;
- •Platelet count ≥ 80 x 109/L ;
- •Hemoglobin ≥ 10 g/dL.
- •Adequate renal function defined as creatinine ≤ 2 mg/dL, unless secondary to lymphoma;
- •Adequate hepatic function defined as bilirubin ≤ 2 mg/dL, unless secondary to lymphoma;
- •Left Ventricular Ejection Fraction (LVEF) > 50% at bidimensional echocardiogram (mandatory only for patients receiving R/G-CHOP);
- •Life expectancy ≥ 6 months;
- •Subject understands and voluntarily signs an informed consent form approved by an Independent Ethics Committee (IEC) prior to the initiation of any screening or study-specific procedures;
- •Subject must be able to adhere to the study visit schedule and other protocol requirements;
- •Women of childbearing potential (WOCBP) and men must agree to use effective contraception if sexually active. This applies for the time period between signing of the informed consent form and 12 months after last rituximab dose or 18 months after last obinutuzumab dose. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control (failure rate of less than 1%) e.g., intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner. The use of condoms by male patients is required (even if surgically sterilized, i.e., status post vasectomy) unless the female partner is permanently sterile. Full sexual abstinence is admitted when this is in line with the preferred and usual lifestyle of the subject, for the same time period planned for other methods of birth control (see above). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods for the female partner) and withdrawal are not acceptable methods of contraception).
排除标准
- •Histological diagnosis different from FL grade 1-3a WHO 2017 classification;
- •Suspect or clinical evidence of Central Nervous System (CNS) involvement by lymphoma;
- •Contraindication to the use of anti-CD20 monoclonal antibodies;
- •Subject has received any anticancer therapy (chemotherapy, immunotherapy, investigational therapy, including targeted small molecule agents) within 14 days prior to the first dose of study drug;
- •Noteworthy history of neurologic, psychiatric, endocrinological, metabolic, immunologic, or hepatic disease that would preclude participation in the study or compromise ability to give informed consent;
- •Any history of other active malignancies within 3 years prior to study entry, with the exception of: adequately treated in situ carcinoma of the cervix uterine; basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; limited stage surgically removed breast cancer or adequately treated with radiation therapy; limited stage prostate carcinoma surgically removed or adequately treated with radiation therapy; previous malignancy confined and surgically resected with curative intent;
- •Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
- •Uncontrolled and/or active systemic infection (viral, bacterial or fungal), including active ongoing infection from SARS-CoV-2;
- •Chronic or acute hepatitis B (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e., HBsAg negative, HBsAb positive and HBcAb negative) or positive HBcAb from previous infection or intravenous immunoglobulins (IVIG) may participate; inactive carriers (HBsAg positive with undetectable HBV- DNA) are eligible. Patients with presence of HCV antibody are eligible only if Polymerase Chain Reaction (PCR) negative for HCV-RNA;
- •Women who are pregnant or breastfeeding.
研究组 & 干预措施
Standard arm (A)
Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).
Patients randomized to Arm A will receive an induction immunochemotherapy at full doses (standard schedule).
After cycle 4, patients will be assessed for response and will complete their planned therapy if at least a stable disease is confirmed.
At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction.
干预措施: Immunochemotherapy regimen: G-CVP (Arm A) (Drug)
Standard arm (A)
Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).
Patients randomized to Arm A will receive an induction immunochemotherapy at full doses (standard schedule).
After cycle 4, patients will be assessed for response and will complete their planned therapy if at least a stable disease is confirmed.
At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction.
干预措施: Immunochemotherapy regimen: Rituximab-bendamustine (Arm A) (Drug)
Standard arm (A)
Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).
Patients randomized to Arm A will receive an induction immunochemotherapy at full doses (standard schedule).
After cycle 4, patients will be assessed for response and will complete their planned therapy if at least a stable disease is confirmed.
At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction.
干预措施: Immunochemotherapy regimen: R-CHOP (Arm A) (Drug)
Standard arm (A)
Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).
Patients randomized to Arm A will receive an induction immunochemotherapy at full doses (standard schedule).
After cycle 4, patients will be assessed for response and will complete their planned therapy if at least a stable disease is confirmed.
At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction.
干预措施: Immunochemotherapy regimen: G-bendamustine (Arm A) (Drug)
Standard arm (A)
Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).
Patients randomized to Arm A will receive an induction immunochemotherapy at full doses (standard schedule).
After cycle 4, patients will be assessed for response and will complete their planned therapy if at least a stable disease is confirmed.
At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction.
干预措施: Immunochemotherapy regimen: G-CHOP (Arm A) (Drug)
Experimental arm (B)
Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).
Patients randomized to Arm B will start their induction treatment with 4 cycles of the immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be assessed for response and will proceed with subsequent treatment based on the quality of their response. Specifically:
- Patients achieving a CR will receive a shortened treatment: in detail, they won't receive any further chemotherapy but will complete induction with 4 additional cycles of only the Monoclonal Antibody (MoAb) given during the first four cycles;
- In case if response less than CR, (PR,SD), patients will complete treatment as planned for patients in Arm A.
At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction.
干预措施: Immunochemotherapy regimen: Rituximab-bendamustine (Arm B) (Drug)
Experimental arm (B)
Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).
Patients randomized to Arm B will start their induction treatment with 4 cycles of the immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be assessed for response and will proceed with subsequent treatment based on the quality of their response. Specifically:
- Patients achieving a CR will receive a shortened treatment: in detail, they won't receive any further chemotherapy but will complete induction with 4 additional cycles of only the Monoclonal Antibody (MoAb) given during the first four cycles;
- In case if response less than CR, (PR,SD), patients will complete treatment as planned for patients in Arm A.
At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction.
干预措施: Immunochemotherapy regimen: R-CHOP (Arm B) (Drug)
Experimental arm (B)
Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).
Patients randomized to Arm B will start their induction treatment with 4 cycles of the immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be assessed for response and will proceed with subsequent treatment based on the quality of their response. Specifically:
- Patients achieving a CR will receive a shortened treatment: in detail, they won't receive any further chemotherapy but will complete induction with 4 additional cycles of only the Monoclonal Antibody (MoAb) given during the first four cycles;
- In case if response less than CR, (PR,SD), patients will complete treatment as planned for patients in Arm A.
At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction.
干预措施: Immunochemotherapy regimen: G-bendamustine (Arm B) (Drug)
Experimental arm (B)
Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).
Patients randomized to Arm B will start their induction treatment with 4 cycles of the immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be assessed for response and will proceed with subsequent treatment based on the quality of their response. Specifically:
- Patients achieving a CR will receive a shortened treatment: in detail, they won't receive any further chemotherapy but will complete induction with 4 additional cycles of only the Monoclonal Antibody (MoAb) given during the first four cycles;
- In case if response less than CR, (PR,SD), patients will complete treatment as planned for patients in Arm A.
At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction.
干预措施: Immunochemotherapy regimen: G-CHOP (Arm B) (Drug)
Experimental arm (B)
Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).
Patients randomized to Arm B will start their induction treatment with 4 cycles of the immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be assessed for response and will proceed with subsequent treatment based on the quality of their response. Specifically:
- Patients achieving a CR will receive a shortened treatment: in detail, they won't receive any further chemotherapy but will complete induction with 4 additional cycles of only the Monoclonal Antibody (MoAb) given during the first four cycles;
- In case if response less than CR, (PR,SD), patients will complete treatment as planned for patients in Arm A.
At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction.
干预措施: Immunochemotherapy regimen: G-CVP (Arm B) (Drug)
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: The endpoint will be assessed from the beginning of the study up to 104 months (end of study)
The length of time during and after the treatment that patients live with the disease, but it does not get worse. Progression-Free Survival (PFS) will be measured from the time of study entry to documented progression or to the patient's death as a result of any causes. Subjects with incomplete follow-up or with no disease evaluation will be censored at the date of last available documented status of freedom from failure.
次要结局
- Molecular response(The endpoint will be assessed from the beginning of the study up to 104 months (end of study))
- Event-Free Survival (EFS)(The endpoint will be assessed from the beginning of the study up to 104 months (end of study))
- Patient-Reported Outcomes (PROs)(The endpoint will be assessed from the beginning of the study up to 104 months (end of study))
- Incidence of toxicities (Safety of the treatment)(The endpoint will be assessed from the beginning of the study up to 104 months (end of study))
- Overall Survival (OS)(The endpoint will be assessed from the beginning of the study up to 104 months (end of study))
- Overall Response rate (ORR)(The endpoint will be assessed from the beginning of the study up to 104 months (end of study))
- Complete response rate (CRR)(The endpoint will be assessed from the beginning of the study up to 104 months (end of study))